The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis
Authors:
Open Access
- 27 March 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 14, 158
Abstract
Stuttering is a DSM V psychiatric condition for which there are no FDA-approved medications for treatment. A growing body of evidence suggests that dopamine antagonist medications are effective in reducing the severity of stuttering symptoms. Stuttering shares many similarities to Tourette's Syndrome in that both begin in childhood, follow a similar male to female ratio of 4:1, respond to dopamine antagonists, and symptomatically worsen with dopamine agonists. In recent years, advances in the neurophysiology of stuttering have helped further guide pharmacological treatment. A newer medication with a novel mechanism of action, selective D1 antagonism, is currently being investigated in FDA trials for the treatment of stuttering. D1 antagonists possess different side-effect profiles than D2 antagonist medications and may provide a unique option for those who stutter. In addition, VMAT-2 inhibitors alter dopamine transmission in a unique mechanism of action that offers a promising treatment avenue in stuttering. This review seeks to highlight the different treatment options to help guide the practicing clinician in the treatment of stuttering.Keywords
This publication has 68 references indexed in Scilit:
- Mutations in the Lysosomal Enzyme–Targeting Pathway and Persistent StutteringNew England Journal of Medicine, 2010
- How the brain repairs stutteringBrain, 2009
- Association between dopaminergic genes (SLC6A3 and DRD2) and stuttering among Han ChineseJournal of Human Genetics, 2009
- Case Report of Aripiprazole for Persistent Developmental StutteringJournal of Clinical Psychopharmacology, 2008
- Genetic studies of stuttering in a founder populationJournal of Fluency Disorders, 2007
- Stuttering and StimulantsJournal of Clinical Psychopharmacology, 1991
- A double‐blind study of verapamil in the treatment of stutteringInternational Journal of Language & Communication Disorders, 1988
- Patterns of regional cerebral blood flow during attempted reading aloud by stutterers both on and off haloperidol medication: Evidence for inadequate left frontal activation during stuttering*1Brain and Language, 1980
- Results of the Treatment of Severe Forms of Stuttering in AdultsFolia Phoniatrica et Logopaedica, 1975
- A Contribution to Pharmacotherapy of Stuttering and ClutteringFolia Phoniatrica et Logopaedica, 1970